Reversal of anticoagulant effects in patients with intracerebral hemorrhage.
Review published in Current neurology and neuroscience reports (2015)
Abstract
Anticoagulant therapies are increasingly being used for the treatment and prevention of thromboembolic diseases. A growing incidence of anticoagulant-associated intracranial hemorrhage (AICH) has accompanied the rise in their use. Although the rate of intracerebral hemorrhage (ICH) in patients receiving anticoagulation therapies such as heparin and target-specific oral anticoagulants (TSOAs) is significantly lower than that of vitamin K antagonists (VKAs), the mortality rate remains high. TSOAs have only recently become available for use in clinical practice, and presently, there is a paucity of both clinical data and evidence-based guidelines to assist in the management of TSOA-associated intracerebral hemorrhage. In this article, we review current literature and provide physicians with diagnostic and therapeutic considerations for the management of AICH.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Anticoagulant therapies are increasingly being used for the treatment and prevention of thromboembolic diseases. A growing incidence of anticoagulant-associated intracranial hemorrhage (AICH) has accompanied the rise in their use.
Why This Matters for Hirudotherapy
This narrative review surveys the diagnosis and management of anticoagulant-associated intracranial hemorrhage (AICH), noting that while target-specific oral anticoagulants (TSOAs) and heparin carry a lower intracerebral-hemorrhage rate than vitamin K antagonists, mortality stays high and evidence-based reversal guidance for TSOA-associated bleeds remains sparse. For ASH it frames the clinical safety boundary around any anticoagulant strategy: the medicinal-leech secretome contributes potent direct thrombin inhibitors (hirudin) and other antithrombotics to the drug-discovery pipeline, so the same bleeding-management questions raised here apply whenever leech-derived anticoagulation is considered, and the recognized challenge of reversing these agents underscores why caution is warranted near the central nervous system. This is a review article summarizing other studies rather than original trial data, and it does not address hirudotherapy or leech-derived compounds directly; it is context for the anticoagulant-safety landscape, not evidence for clinical leech use.
Citation
Reversal of anticoagulant effects in patients with intracerebral hemorrhage.
Yates et al. · Current neurology and neuroscience reports, 2015
Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026